Streetbeat News

Analyst Ratings

IOVA

Investors have shown a mixed sentiment towards Iovance Biotherapeutics (NASDAQ:IOVA), with options trading revealing 47% bullish and 52% bearish positions. A significant volume of options trades, including both calls and puts, indicates a targeted price range of $10.0 to $25.0 for IOVA. The company, a pioneer in T-cell therapy for solid tumor cancers, is preparing for potential U.S. regulatory approval. Analysts have given IOVA an average target price of $23.0, with ratings ranging from Buy to Market Outperform.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 5:30 pm

CHDN

JMP Securities analyst Jordan Bender has maintained a Market Outperform rating on Churchill Downs (NASDAQ:CHDN) and increased the price target from $148 to $150.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:28 pm

WULF

Cantor Fitzgerald analyst Josh Siegler has maintained an Overweight rating on TeraWulf (NASDAQ:WULF) and increased the price target from $3 to $4.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:23 pm

HRMY

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $49 price target.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:20 pm

BMRN

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Biomarin Pharmaceutical (BMRN) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:18 pm

ITCI

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $101 price target.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:13 pm

AUPH

Cantor Fitzgerald analyst Olivia Brayer maintains an Overweight rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) but lowers the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:11 pm

INTU

Intuit Inc (NASDAQ:INTU) reported in-line revenues and an earnings beat for Q4. Analysts from Stifel, Mizuho Securities, Oppenheimer, Piper Sandler, and William Blair are bullish on Intuit's AI strategy and have raised their price targets. The company's performance was highlighted by strong results in the Small Business segment and expectations of a return to a normalized tax season. Shares of Intuit rose by 0.87% to $663.64.

Portfolio Pulse from Priya Nigam

February 23, 2024 | 5:11 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer has maintained a Neutral rating on Alnylam Pharmaceuticals (ALNY) and reduced the price target from $165 to $150.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:09 pm

RCEL

Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on AVITA Medical (NASDAQ:RCEL) and raises the price target from $22 to $25.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:05 pm